Why This Beaten-Down Stock Is a Buy in 2025 and Beyond
The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
TORONTO, ON / ACCESS Newswire / / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and ...